BLM Helicase Inhibition Synergizes with PARP Inhibition to Improve the Radiosensitivity of Olaparib Resistant Non-Small Cell Lung Cancer Cells by Inhibiting Homologous Recombination Repair

Scientists investigated the radiosensitizing efficacy of the poly-ADP-ribose polymerase (PARP) inhibitor, olaparib, and the bloom syndrome protein (BLM) helicase inhibitor, ML216, in NSCLC cells.